Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy

Name: Αlpha¹ Rigor Record — Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy
Item: Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy
Rating: 59
Author: Αlpha¹

Mamounas EP, Bandos H, White JR, Julian TB, Khan AJ, Shaitelman SF, Torres MA, Vicini FA, Ganz PA, McCloskey SA, Lucas PC, Gupta N, Li XA, McCormick B, Smith B, Tendulkar RD, Kavadi VS, Matsumoto K, Seaward SA, Irvin WJ, Lin JY, Mutter RW, Muanza TM, Stromberg J, Jagsi R, Weiss AC, Curran WJ, Wolmark N.

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 2.75★ (Weak), 0 critical, 5 high issues for “Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 10, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

2.75 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
ClaimsOverstated claim−0.5★
ReportingBiological variables not met−0.5★
ReportingData & code availability not met−0.5★
ReportingEthical approvals partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.29.0Source: full text

Problems surfaced6 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions1

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions overstated beyond the evidenceAssessed

Reporting gaps3

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Biological variables not reportedAssessed
Data and code not sharedAssessed
Ethics/consent reporting incompleteAssessed

Copyediting1

Wording, consistency and formatting errors that need correcting before submission.

Wording or formatting errors that need correctingAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a rigorously designed and transparently reported phase 3 randomized trial (NSABP B-51/RTOG 1304) with a strong scientific premise, detailed methods, prespecified power analysis, ITT analysis, disclosed limitations/funding, and conservative conclusions. Its main weaknesses are reporting gaps: no data availability statement, no sex/health-status reporting, no named ethical-framework compliance statement, and an under-specified randomization method, plus a numerical inconsistency (1,802 vs 1,602) and an overstated predictive claim.

Both independent reviewers agreed on 7 of 8 dimension statuses and diverged only on key resources (pass vs not applicable), which was resolved as applicable-and-pass because the trial's investigational radiation intervention is a scored resource. The statistics component recomputed only 1 test/estimate (consistent); all other statistics are unverified, not confirmed. Citation screening found 0 retracted and 0 not-found references. Copyedit flagged one major internal-contradiction typo (1,802 vs 1,602).

8 major claims checked against the paper's own evidence: 1 not fully backed by the presented evidence (unsupported or overstated).

Recomputed 1 test: 1 consistent, 0 inconsistent; 1 recomputed directly from the reported test statistics.

1 integrity concern flagged (0 high).

Reporting

Eight Dimensions5 pass · 1 warn · 2 fail

The introduction cites relevant trials and retrospective analyses, acknowledges the gap in knowledge, and provides a logical rationale for the study. The limitations of prior research are addressed, and the hypothesis follows from the cited evidence.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The paper clearly establishes the scientific premise by citing prior research on regional nodal irradiation and the lack of prospective data for this patient population.

Evidence

direct quote[Introduction, paragraph 1]

“Adjuvant regional nodal irradiation has been shown to reduce the risk of locoregional recurrence, distant recurrence, and death from breast cancer among patients with early-stage breast cancer who undergo surgery first and have pathologically involved axillary lymph nodes.”